Related Experiment Video
Updated: Feb 22, 2026
Laparoscopic Radical Gastrectomy for Remnant Gastric Cancer
Published on: October 31, 2025
Re-sleeve gastrectomy: single-center insight into controversial territory.
Pearl Ma1, Luis Felipe Okida2, Morgan McGrath3
1Advanced Laparoscopic Surgical Associates, Community Medical Hospitals, Fresno, California; Department of surgery, University of California San Francisco - Fresno, Fresna, California; Department of Minimally Invasive and Bariatric Surgery, Fresno Heart and Surgical Hospital, Fresno, California.
Re-sleeve gastrectomy (ReSG) offers sustained weight loss and improved symptoms for patients with inadequate weight loss after sleeve gastrectomy (SG). This revisional surgery demonstrates acceptable safety and effectiveness in managing weight recurrence.
Area of Science:
- Bariatric Surgery
- Gastrointestinal Surgery
- Metabolic and Bariatric Surgery
Background:
- Re-sleeve gastrectomy (ReSG) is a revisional procedure for inadequate weight loss or regain post-sleeve gastrectomy (SG).
- Its efficacy and safety remain under investigation due to limited data.
Purpose of the Study:
- To evaluate weight loss outcomes after ReSG.
- To assess the safety profile of ReSG.
- To determine the impact of ReSG on gastroesophageal reflux disease (GERD).
Main Methods:
- Retrospective review of 101 patients undergoing ReSG between 2017-2023.
- Analysis of weight loss (%EWL, %TWL), complications, and GERD symptoms.
- Follow-up data collected at 1, 2, and 3 years post-surgery.
Main Results:
- ReSG demonstrated sustained weight loss, with mean %EWL around 63% and %TWL around 31% at 3 years.
- 30-day complication, readmission, and reoperation rates were 7.9%, 9.9%, and 7.9%, respectively.
- Despite increased GERD medication use, reflux symptoms were controlled, and BMI significantly decreased post-ReSG.
Conclusions:
- Re-sleeve gastrectomy is a safe and effective revisional option for managing weight recurrence after SG.
- The procedure offers sustained weight loss and symptom improvement.
- Morbidity associated with ReSG is acceptable.
